>>> US Gapping up


Gapping up
In reaction to strong earnings/guidance
:

  • ORCL +11.3%, CMC +8.6%, HAIN +5.5%, CO +4.5%, APOG +4.1%

M&A news:

  • SPLS +6.8% (Sycamore Partners nearing M&A deal to purchase SPLS, according to Reuters)

Other news:

  • TROV +13.7% (enters into agreement with a worldwide, premier biopharmaceutical company to provide Trovera urine circulating tumor DNA biomarker tests and services)
  • OVAS +8.2% (appoints Christopher Kroeger as CEO effective September 1; will restructure its organization)
  • NRZ +3.1% ( increases quarterly dividend to $0.50 per common share from $0.48 per common share)
  • NVS +2.7% (reports Phase 3 data for ACZ885 demonstrating reduction in cardiovascular risk)
  • SHPG +2.3% (receives EMA Validation of Veyvondi)
  • FGEN +1% (confirms receipt of Orphan Drug Designation by the FDA for Pamrevlumab)

Analyst comments:

  • ATVI +1.3% (target raised to $70 from $60 at Oppenheimer)
  • VLO +1.2% (upgraded to Buy from Hold at Jefferies)